title: Archaeosomes display immunoadjuvant potential for a vaccine against Chagas disease.
abstract: Archaeosomes (ARC), vesicles made from lipids extracted from Archaea, display strong adjuvant properties. In this study, we evaluated the ability of the highly stable ARC formulated from total polar lipids of a new Halorubrum tebenquichense strain found in Argentinean Patagonia, to act as adjuvant for soluble parasite antigens in developing prophylactic vaccine against the intracellular protozoan T. cruzi, the etiologic agent of Chagas disease. We demonstrated for the first time that C3H/HeN mice subcutaneously immunized with trypanosomal antigens entrapped in these ARC (ARC-TcAg) rapidly developed higher levels of circulating T. cruzi antibodies than those measured in the sera from animals receiving the antigen alone. Enhanced humoral responses elicited by ARC-TcAg presented a dominant IgG2a antibody isotype, usually associated with Th1-type immunity and resistance against T. cruzi. More importantly, ARC-TcAg-vaccinated mice displayed reduced parasitemia during early infection and were protected against an otherwise lethal challenge with the virulent Tulahuén strain of the parasite. Our findings suggest that, as an adjuvant, H. tebenquichense-derived ARC may hold great potential to develop a safe and helpful vaccine against this relevant human pathogen.
authors.affiliation: Programa de Nanomedicinas; Departamento de Ciencia y Tecnología; Universidad Nacional de Quilmes; Buenos Aires, Argentina.
authors.forename: Leticia H
authors.initials: LH
authors.lastname: Higa
authors.forename: Ricardo S
authors.initials: RS
authors.lastname: Corral
authors.forename: María José
authors.initials: MJ
authors.lastname: Morilla
authors.forename: Eder L
authors.initials: EL
authors.lastname: Romero
authors.forename: Patricia B
authors.initials: PB
authors.lastname: Petray
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000302:isolation & purification; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D001118:Argentina; D014355:Chagas Disease / Q000276:immunology / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D055352:Halorubrum / Q000737:chemistry*; D007074:Immunoglobulin G / Q000097:blood; D007279:Injections, Subcutaneous; D008081:Liposomes / Q000008:administration & dosage* / Q000302:isolation & purification; D008563:Membrane Lipids / Q000008:administration & dosage* / Q000302:isolation & purification; D008809:Mice, Inbred C3H; D018512:Parasitemia / Q000276:immunology / Q000517:prevention & control; D016052:Protozoan Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D016019:Survival Analysis; D018417:Th1 Cells / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D008081:Liposomes; D008563:Membrane Lipids; D016052:Protozoan Vaccines
keywords: Trypanosoma cruzi; archaeosomes; immunology; nanotechnology; vaccine adjuvants